PCI Biotech $PCIB bullish breaching 100EMA coming into Q4
* Norwegian Drug Delivery Platform Biotech operating within the Oslo Cancer Cluster
* Notoriously volatile norwegian small cap with large amount of stock held by enthusiastic retail investor crowd.
* Ongoing research collaboration with AstraZeneca recently concluded, longs betting on partnership deal incoming.
* Stock typically rallies ahead of quarterly reports and experiences sell the news events.
* Norwegian biotech flying at All Time High valuations after recent Vaccibody partnership with Genentech.
* Notoriously volatile norwegian small cap with large amount of stock held by enthusiastic retail investor crowd.
* Ongoing research collaboration with AstraZeneca recently concluded, longs betting on partnership deal incoming.
* Stock typically rallies ahead of quarterly reports and experiences sell the news events.
* Norwegian biotech flying at All Time High valuations after recent Vaccibody partnership with Genentech.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.